KDR - Wiki-MPM

Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
CSF2RB	colony stimulating factor 2 receptor subunit beta	Interleukin-3, Interleukin-5 and GM-CSF signaling Interleukin-3, Interleukin-5 and GM-CSF signaling RAF/MAP kinase cascade Surfactant metabolism Defective CSF2RB causes SMDP5 Defective CSF2RA causes SMDP4 Interleukin receptor SHC signaling	Sargramostim NPI 32101 Resatorvid
CSNK1D	casein kinase 1 delta	COPII-mediated vesicle transport Regulation of PLK1 Activity at G2/M Transition Loss of Nlp from mitotic centrosomes Recruitment of mitotic centrosome proteins and complexes Loss of proteins required for interphase microtubule organization from the centrosome Recruitment of NuMA to mitotic centrosomes Circadian Clock Anchoring of the basal body to the plasma membrane Major pathway of rRNA processing in the nucleolus and cytosol AURKA Activation by TPX2
CTNNB1	catenin beta 1	Degradation of beta-catenin by the destruction complex Beta-catenin phosphorylation cascade TCF dependent signaling in response to WNT Formation of the beta-catenin:TCF transactivating complex Formation of the beta-catenin:TCF transactivating complex LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production Apoptotic cleavage of cell adhesion proteins Deactivation of the beta-catenin transactivating complex Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) Ca2+ pathway Adherens junctions interactions Binding of TCF/LEF:CTNNB1 to target gene promoters Disassembly of the destruction complex and recruitment of AXIN to the membrane Disassembly of the destruction complex and recruitment of AXIN to the membrane VEGFR2 mediated vascular permeability Myogenesis Myogenesis Signaling by GSK3beta mutants S33 mutants of beta-catenin aren't phosphorylated S37 mutants of beta-catenin aren't phosphorylated S45 mutants of beta-catenin aren't phosphorylated T41 mutants of beta-catenin aren't phosphorylated RHO GTPases activate IQGAPs Transcriptional Regulation by VENTX InlA-mediated entry of Listeria monocytogenes into host cells RUNX3 regulates WNT signaling	Urea	Gastric cancer Colorectal cancer Endometrial Cancer Pilomatricoma; Epithelioma calcificans of Malherbe Thyroid cancer Hepatocellular carcinoma
DNM2	dynamin 2	Toll Like Receptor 4 (TLR4) Cascade Retrograde neurotrophin signalling Gap junction degradation Formation of annular gap junctions NOSTRIN mediated eNOS trafficking MHC class II antigen presentation Lysosome Vesicle Biogenesis Golgi Associated Vesicle Biogenesis Recycling pathway of L1 Clathrin-mediated endocytosis NGF-stimulated transcription		Centronuclear myopathy Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy
DUSP19	dual specificity phosphatase 19
FBXO25	F-box protein 25
FBXW11	F-box and WD repeat domain containing 11	Activation of NF-kappaB in B cells Downstream TCR signaling Regulation of PLK1 Activity at G2/M Transition FCERI mediated NF-kB activation Dectin-1 mediated noncanonical NF-kB signaling CLEC7A (Dectin-1) signaling NIK-->noncanonical NF-kB signaling MAP3K8 (TPL2)-dependent MAPK1/3 activation Neddylation Antigen processing: Ubiquitination & Proteasome degradation
FLT1	fms related receptor tyrosine kinase 1	Neurophilin interactions with VEGF and VEGFR VEGF binds to VEGFR leading to receptor dimerization	Sorafenib Sunitinib Vatalanib TG-100801 OSI-930 Denibulin ABT-869 IMC-1C11 Pazopanib Axitinib N-(4-chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide Regorafenib Lenvatinib Nintedanib Polaprezinc Foreskin fibroblast (neonatal) Fostamatinib Selpercatinib
FLT4	fms related receptor tyrosine kinase 4	VEGF binds to VEGFR leading to receptor dimerization NOTCH4 Intracellular Domain Regulates Transcription	Sorafenib Sunitinib Vatalanib TG-100801 Denibulin ABT-869 IMC-1C11 Pazopanib Axitinib Regorafenib Lenvatinib Nintedanib Fostamatinib Selpercatinib	Lymphedemas, including: Lymphedema, hereditary I; Lymphedema-distichiasis syndrome (LD); Hypotrichosis-lymphedema-telangiectasia syndrome (HLTS)
FRS2	fibroblast growth factor receptor substrate 2	PI3K Cascade PIP3 activates AKT signaling Frs2-mediated activation Frs2-mediated activation Constitutive Signaling by Aberrant PI3K in Cancer PI-3K cascade:FGFR1 FRS-mediated FGFR1 signaling PI-3K cascade:FGFR2 FRS-mediated FGFR2 signaling FRS-mediated FGFR3 signaling PI-3K cascade:FGFR3 FRS-mediated FGFR4 signaling PI-3K cascade:FGFR4 Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Signaling by FGFR3 fusions in cancer Signaling by FGFR3 point mutants in cancer RET signaling Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK2 signals through FRS2 and FRS3
FYN	FYN proto-oncogene, Src family tyrosine kinase	GPVI-mediated activation cascade Signaling by ERBB2 PIP3 activates AKT signaling Signaling by SCF-KIT Signaling by SCF-KIT Regulation of KIT signaling Nef and signal transduction Cell surface interactions at the vascular wall FCGR activation PECAM1 interactions Constitutive Signaling by Aberrant PI3K in Cancer DAP12 signaling DAP12 signaling EPH-Ephrin signaling Role of LAT2/NTAL/LAB on calcium mobilization Nephrin family interactions Nephrin family interactions NCAM signaling for neurite out-growth NCAM signaling for neurite out-growth CD28 co-stimulation CD28 dependent PI3K/Akt signaling CD28 dependent Vav1 pathway CTLA4 inhibitory signaling EPHB-mediated forward signaling EPHB-mediated forward signaling EPHA-mediated growth cone collapse EPHA-mediated growth cone collapse Ephrin signaling Ephrin signaling EPH-ephrin mediated repulsion of cells Sema3A PAK dependent Axon repulsion SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion CRMPs in Sema3A signaling CRMPs in Sema3A signaling VEGFA-VEGFR2 Pathway Dectin-2 family CD209 (DC-SIGN) signaling RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Platelet Adhesion to exposed collagen Reelin signalling pathway Regulation of signaling by CBL Regulation of signaling by CBL FCGR3A-mediated IL10 synthesis FCGR3A-mediated phagocytosis Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants FLT3 signaling through SRC family kinases Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Dasatinib Triglyme Fostamatinib
GABARAP	GABA type A receptor-associated protein	Macroautophagy TBC/RABGAPs
GNA11	G protein subunit alpha 11	Acetylcholine regulates insulin secretion Acetylcholine regulates insulin secretion G alpha (q) signalling events G alpha (q) signalling events ADP signalling through P2Y purinoceptor 1 ADP signalling through P2Y purinoceptor 1 Thromboxane signalling through TP receptor Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion Thrombin signalling through proteinase activated receptors (PARs)
GNAQ	G protein subunit alpha q	Acetylcholine regulates insulin secretion Acetylcholine regulates insulin secretion G alpha (q) signalling events G alpha (q) signalling events ADP signalling through P2Y purinoceptor 1 ADP signalling through P2Y purinoceptor 1 Thromboxane signalling through TP receptor Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion Thrombin signalling through proteinase activated receptors (PARs)
GRB10	growth factor receptor bound protein 10	Signaling by SCF-KIT IRS activation Signal attenuation Insulin receptor signalling cascade RET signaling FLT3 Signaling Response of EIF2AK1 (HRI) to heme deficiency
GRB2	growth factor receptor bound protein 2	Interleukin-15 signaling Interleukin-15 signaling STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants	Pegademase 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
HSP90AA1	heat shock protein 90 alpha family class A member 1	Signaling by ERBB2 Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation vRNP Assembly Regulation of actin dynamics for phagocytic cup formation eNOS activation Regulation of PLK1 Activity at G2/M Transition Scavenging by Class F Receptors Scavenging by Class F Receptors HSP90 chaperone cycle for steroid hormone receptors (SHR) HSF1 activation Attenuation phase HSF1-dependent transactivation Loss of Nlp from mitotic centrosomes Recruitment of mitotic centrosome proteins and complexes Loss of proteins required for interphase microtubule organization from the centrosome Recruitment of NuMA to mitotic centrosomes Sema3A PAK dependent Axon repulsion VEGFA-VEGFR2 Pathway VEGFA-VEGFR2 Pathway VEGFR2 mediated vascular permeability Uptake and function of diphtheria toxin PIWI-interacting RNA (piRNA) biogenesis Anchoring of the basal body to the plasma membrane Constitutive Signaling by EGFRvIII Regulation of necroptotic cell death Interleukin-4 and Interleukin-13 signaling Neutrophil degranulation The role of GTSE1 in G2/M progression after G2 checkpoint AURKA Activation by TPX2 Downregulation of ERBB2 signaling ESR-mediated signaling Extra-nuclear estrogen signaling RHOBTB2 GTPase cycle Estrogen-dependent gene expression Chaperone Mediated Autophagy Constitutive Signaling by Overexpressed ERBB2 Aggrephagy Drug-mediated inhibition of ERBB2 signaling Signaling by ERBB2 KD Mutants Resistance of ERBB2 KD mutants to trastuzumab Resistance of ERBB2 KD mutants to sapitinib Resistance of ERBB2 KD mutants to tesevatinib Resistance of ERBB2 KD mutants to neratinib Resistance of ERBB2 KD mutants to osimertinib Resistance of ERBB2 KD mutants to afatinib Resistance of ERBB2 KD mutants to AEE788 Resistance of ERBB2 KD mutants to lapatinib Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Drug resistance in ERBB2 TMD/JMD mutants Potential therapeutics for SARS	Rifabutin Nedocromil 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-9h-Purin-6-Ylamine Geldanamycin 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-2-Fluoro-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine 9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine 4-(1,3-Benzodioxol-5-Yl)-5-(5-Ethyl-2,4-Dihydroxyphenyl)-2h-Pyrazole-3-Carboxylic Acid 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9-Pent-9h-Purin-6-Ylamine 9-Butyl-8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9h-Purin-6-Ylamine 4-(1h-Imidazol-4-Yl)-3-(5-Ethyl-2,4-Dihydroxy-Phenyl)-1h-Pyrazole 9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine 9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine Quercetin 8-Benzo[1,3]Dioxol-,5-Ylmethyl-9-Butyl-2-Fluoro-9h-Purin-6-Ylamine 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine N-[4-(AMINOSULFONYL)BENZYL]-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE Tanespimycin SNX-5422 N-(4-ACETYLPHENYL)-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE 4-CHLORO-6-(4-{4-[4-(METHYLSULFONYL)BENZYL]PIPERAZIN-1-YL}-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-PIPERAZIN-1-YL-1H-PYRAZOLE-3-CARBOXAMIDE 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE 2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL (3E)-3-[(phenylamino)methylidene]dihydrofuran-2(3H)-one 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE 3-({2-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)ETHYNYL]BENZYL}AMINO)-1,3-OXAZOL-2(3H)-ONE N-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)METHYL]-3-{[(E)-(2-OXODIHYDROFURAN-3(2H)-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE 4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol CCT-018159 4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol 8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE 4-methyl-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-amine (5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H- 4-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol 2-[(2-methoxyethyl)amino]-4-(4-oxo-1,2,3,4-tetrahydro-9H-carbazol-9-yl)benzamide 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine 4-(2,4-dichlorophenyl)-5-phenyldiazenyl-pyrimidin-2-amine 3,6-DIAMINO-5-CYANO-4-(4-ETHOXYPHENYL)THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE 2-AMINO-4-(2,4-DICHLOROPHENYL)-N-ETHYLTHIENO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE Copper Polaprezinc Alvespimycin
ILKAP	ILK associated serine/threonine phosphatase
IQGAP1	IQ motif containing GTPase activating protein 1	Nephrin family interactions Glucagon-like Peptide-1 (GLP1) regulates insulin secretion RHO GTPases activate IQGAPs MAP2K and MAPK activation Neutrophil degranulation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants	Artenimol
ITGB3	integrin subunit beta 3	Platelet degranulation Elastic fibre formation PECAM1 interactions Molecules associated with elastic fibres Integrin cell surface interactions Integrin cell surface interactions Syndecan interactions Syndecan interactions ECM proteoglycans Integrin signaling GRB2:SOS provides linkage to MAPK signaling for Integrins p130Cas linkage to MAPK signaling for integrins VEGFA-VEGFR2 Pathway Signal transduction by L1 MAP2K and MAPK activation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants	Abciximab Eptifibatide Antithymocyte immunoglobulin (rabbit) Levothyroxine Tirofiban Resveratrol Lefradafiban LM-609 Fradafiban Ferric maltol	Glanzmann thrombasthenia Allograft rejection

Search Results for: KDR